In fact, Johnson & Johnson’s one-time coronavirus vaccine may consist of two doses, Biden’s government said.
The vaccine, which was recently submitted to the U.S. Food and Drug Administration (FDA) for approval, has been hailed as one of the most effective ways to increase supply and push President Joe Biden closer to his target of 150 million gunshots. bring. first 100 days of his term.
J&J is currently on track to produce 100 million doses of its single-shot vaccine, but is trying to find a way to update immunization in light of variants.
However, during a Washington Post Live eventAndy Slavitt, the White House’s senior advisor on the response to COVID-19, says the company is currently testing the effectiveness of its shot with a booster.
“Johnson & Johnson is currently evaluating how their vaccine is performing with two doses, in other words with their own booster,” he told host Jonathan Capehart, a columnist for the newspaper’s opinion piece.
Pending the results of that, pending what the FDA has to say – if the vaccine is approved in the first place – there could be a second injection of Johnson & Johnson. ‘
The news has raised concerns that the US may not be able to immunize enough of the population before the more contagious variants from the UK and South Africa become dominant in the US.
Johnson & Johnson’s one-time coronavirus vaccine could, in fact, be two doses, Andy Slavitt, the White House’s senior advisor for the response to COVID-19, said Thursday. Pictured: J&J vaccine vials against COVID-19 seen at Klerksdorp Hospital in South Africa, Feb. 18
Slavitt (pictured) told The Washington Post Live that J&J is testing the effectiveness of its vaccine with a booster and that the single-shot two
The single shot has been hailed as one of the most effective ways to help President Biden’s goal of 150 million doses delivered in 100 days. The US is currently vaccinating between 1.6 and 1.7 million people a day
J & J’s vaccine was found to be 66 percent of the prevention of infections in its large global trial, but only 57 percent effective in tests in South Africa.
It is unclear whether this will delay FDA approval of the vaccine for emergency use authorization.
If regulators approve the vaccine, it would be the third injection to be made available to the U.S. public after vaccines from Pfizer Inc / BioNTech SE and Moderna Inc were approved in December.
Unlike Pfizer and Moderna’s two currently approved vaccines, J & Js do not need to be shipped frozen.
It also doesn’t use new mRNA technology, but rather combines genetic material from the new virus with the genes from the adenovirus – which causes the common cold – to trigger an immune response.
It’s the same technology the company used in late 2019 to create an experimental Ebola vaccine for people in the Democratic Republic of Congo.
Currently, 40.2 million Americans – 12.2% of the population – have received one dose and 15.4 million – 4.6% of the population – are fully immunized
Slavitt says states have used 46% of their vaccine stock to 75% since Biden took office Jan. 20
After the J&J application, supervisors need time to analyze the data and an advisory committee will have to meet.
Last month, Dr. Paul Stoffels, J & J’s Chief Scientific Office, that J&J is on track to roll out the vaccine in March.
It remains unclear whether this recent revelation by Slavitt will affect the rollout.
The US has entered into an agreement to purchase 100 million doses of J & J’s vaccine for $ 1 billion, and the option to purchase an additional 200 million doses.
On Thursday, Dr. Fauci confirmed that J&J is still on track for this goal of its single dose and confirmed that the company is making a two-dose dose.
This costs the vaccine around $ 10 per dose, but the New Jersey drug company has promised not to price its vaccinations for profit.
In comparison, the US pays $ 19.50 per dose for the Pfizer immunization and $ 32 to $ 37 per dose of Moderna’s shot.
Meanwhile, the injection being developed by AstraZeneca and the University of Oxford is estimated to cost between $ 3 and $ 4 per dose.
J&J said it is aiming for a billion doses by 2021 with production in the United States, Europe, South Africa and India.
President Biden Aims To Get 150 Million Shots Into Americans Arms By The End Of April, His First 100 Days In Office
Slavitt told Washington Post Live states have gone from 46 percent to 75 percent of their stock since Biden took office.
He added that enough vaccines are currently being purchased to vaccinate everyone in the US by July, but the J&J vaccine is not.
“We’ll let the FDA make the decision and take nothing,” Slavitt said.
This is part of letting science take the lead and not pushing the White House from the side. ‘
